Marketfy
Financial Data & APIs
Events
Premarket Prep
Membership is Free
What are you waiting for? Sign up now!
Name:
Username available!
Username taken!
Email:
Email available!
Email taken!
Password:
Leave blank:
OR
Free Account Login
Click here to access your premium account
Username or email:
Password:
OR
Forgot password?
Contribute
Login
Join
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap
Cryptocurrency
Penny Stocks
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Catalyst
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Tech
Start-Ups
Fintech
Investing
Best Online Brokers
Personal Finance
Compare Brokers
Ally Invest Review
Binary Options Review
eOption
Etrade Review
Forex.com Review
Interactive Brokers Review
Personal Capital Review
Suretrader Review
TD Ameritrade Review
Tradestation Review
Yewno|Edge Review
Cannabis
Premium
Market Overview
Tickers
Articles
Keywords
Search by keyword...
googlecse
WANT TO CATCH
PTIE
NEWS
BEFORE
IT CHANGES THE STOCK PRICE?
More From
Summary
Ideas
Twitter ($)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries
Pain Therapeutics
:
Add to Watchlist +
Trade
{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists
Sector:
Industry:
0.0000
0 (%)
Data as of Dec 05, 2019
Prev. Close
Price Open
Volume
0
Day's Range
-
52 Wk Range
-
50 Day Moving Avg.
PE Ratio
Shares Outstanding
Market Cap
Trade PTIE stock with
recommended broker Ally Invest
. Commissions as low as $3.95.
1d
5d
1m
3m
1y
5y
YTD
Analyst Rating
View All Ratings
Date
Research Firm
Action
Current
Target
9/13/16
Gabelli & Co.
Downgrades
Buy
Hold
5/08/13
Gabelli & Co.
Downgrades
Buy
Hold
11/01/12
CK Cooper
Downgrades
Buy
Hold
Headlines
Press Releases
Pain Therapeutics Reports Name Change To Cassava Sciences, Will Change Ticker To 'SAVA'
Benzinga Newsdesk
Wed, 27 Mar 2019 07:30:51 -0500
Pain Therapeutics Q4 EPS $(0.04) Up From $(0.37) YoY
Benzinga Newsdesk
Mon, 25 Mar 2019 07:33:13 -0500
Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols
Benzinga Newsdesk
Thu, 21 Mar 2019 06:37:57 -0500
Pain Therapeutics 13G Shows New 6.4% Stake From Hudson Bay Capital Management
Benzinga Newsdesk
Tue, 05 Feb 2019 13:14:34 -0500
Pain Therapeutics shares are trading lower after the company said it is no closer to FDA approval for REMOXY following a recent meeting with the FDA.
Benzinga  Newsdesk
Tue, 05 Feb 2019 08:47:59 -0500
Pain Therapeutics Announces Feedback From Recent Meeting With FDA On REMOXY To Resolve Disagreements With FDA; FDA Denied Making Errors Or Material Mistakes During Advisory Committee Meeting, Co. Says It Is No Closer To Product Approval
Benzinga Newsdesk
Tue, 05 Feb 2019 08:07:46 -0500
Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin
Benzinga Newsdesk
Thu, 17 Jan 2019 09:08:14 -0500
Pain Therapeutics Awarded $1.5M Research Grant By National Institutes Of Health
Benzinga Newsdesk
Wed, 16 Jan 2019 09:04:10 -0500
The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results
Shanthi Rexaline
Sun, 23 Dec 2018 10:37:02 -0500
Pain Therapeutics S-1 Shows Registration For ~9.127M Common Share Issuable Upon Exercise Of Warrants Offering Via Selling Shareholders
Benzinga Newsdesk
Tue, 18 Dec 2018 17:33:12 -0500
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Pain Therapeutics Announces Name Change to Cassava Sciences, Inc.
Globe Newswire
Mar 27, 2019
Pain Therapeutics Reports 2018 Financial Results and Corporate Update
Globe Newswire
Mar 25, 2019
Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY
Globe Newswire
Feb 05, 2019
Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin
Globe Newswire
Jan 17, 2019
Pain Therapeutics Awarded $1.5 Million Research Grant by National Institutes of Health
Globe Newswire
Jan 16, 2019
Pain Therapeutics Announces Two New Peer-Reviewed Publications for REMOXY
Globe Newswire
Jan 07, 2019
Pain Therapeutics Announces Filing of Registration Statement on SEC Form S-1
Globe Newswire
Dec 18, 2018
Pain Therapeutics Announces Initiation of a Phase II Study in Alzheimer's Disease
Globe Newswire
Dec 06, 2018
Pain Therapeutics Appeals FDA Decision on REMOXY
Globe Newswire
Nov 12, 2018
Pain Therapeutics Reports Third Quarter 2018 Financial Results
Globe Newswire
Oct 29, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Partner Headlines
Pain Therapeutics now Cassava Sciences
Seeking Alpha
Mar 27, 2019
Purdue Pharma settles opioid case in OK for $270M
Seeking Alpha
Mar 26, 2019
Healthcare stocks stand out among premarket losers
Seeking Alpha
Mar 25, 2019
Pain Therapeutics reports Q4 results
Seeking Alpha
Mar 25, 2019
Painkiller stocks in the red on possible Purdue bankruptcy
Seeking Alpha
Mar 04, 2019
FDA finalizes guidance for developing meds for opioid dependence
Seeking Alpha
Feb 06, 2019
Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers
Seeking Alpha
Feb 05, 2019
Pain Therapeutics down 23% premarket on lack of progress with Remoxy NDA refiling
Seeking Alpha
Feb 05, 2019
OPK and CHD among premarket losers
Seeking Alpha
Feb 05, 2019
Study links opioid prescriptions to marketing spend
Seeking Alpha
Jan 18, 2019
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
News Sentiment
Powered by StockSnips
Now:
Neutral
75.33% Positive
Brokerage Center
Compare All Online Brokerages
Book A Demo
Learn How You Can Succeed In The
Market With Benzinga Pro
Fastest Market News
Real-Time News Alerts
Customizable News Filters
Book A Demo